Search Results - "MARINOV, Iuri"

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients by Polivkova, Vaclava, Rohon, Peter, Klamova, Hana, Cerna, Olga, Divoka, Martina, Curik, Nikola, Zach, Jan, Novak, Martin, Marinov, Iuri, Soverini, Simona, Faber, Edgar, Machova Polakova, Katerina

“…Bone marrow transplantation or ponatinib treatment are currently recommended strategies for management of patients with chronic myeloid leukemia (CML)…”
Get full text

FYA silencing by the GATA-motif variant FYA(−69C) in a Caucasian family by Písačka, Martin, Marinov, Iuri, Králová, Miroslava, Králová, Jana, Kořánová, Michaela, Bohoněk, Miloš, Sood, Chhavi, Ochoa-Garay, Gorka

“…BACKGROUND The c.1‐67C variant polymorphism in a GATA motif of the FY promoter is known to result in erythroid‐specific FY silencing, that is, in Fy(a−) and…”
Get full text

Intra‐ and interlaboratory variability of paroxysmal nocturnal hemoglobinuria testing by flow cytometry following the 2012 Practical Guidelines for high‐sensitivity paroxysmal nocturnal hemoglobinuria testing by Marinov, Iuri, Kohoutová, Martina, Tkáčová, Vlasta, Lysák, Daniel, Holubová, Monika, Stehlíková, Olga, Železníková, Tatiana, Žontar, Darja, Illingworth, Andrea

“…Background Sutherland et al. recently published the Practical Guidelines for high‐sensitivity detection of paroxysmal nocturnal hemoglobinuria (PNH) clones by…”
Get full text

Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness by Motovska, Zuzana, Widimsky, Petr, Petr, Robert, Bilkova, Dana, Marinov, Iuri, Simek, Stanislav, Kala, Petr

“…Abstract Background The optimal timing for 600 mg clopidogrel pre-treatment before planned PCI in patients with stable coronary artery disease has never been…”
Get full text

Clopidogrel resistance "Live" - the risk of stent thrombosis should be evaluated before procedures by Motovska, Zuzana, Widimsky, Petr, Marinov, Iuri, Petr, Robert, Hajkova, Jaroslava, Kvasnicka, Jan

“…Every year, millions of people undergo percutaneous coronary intervention (PCI) with intracoronary stent implantation. A patient from the PRAGUE-8 trial…”
Get full text

Molecular Mechanisms Underlying Abnormal Activation of T Cells in Idiopathic Aplastic Anemia and Hypoplastic Myelodysplastic Neoplasms by Lenertová, Zuzana, Kaisrlikova, Monika, Kundrat, David, Votavova, Hana, Vesela, Jitka, Trsová, Iva, Ransdorfova, Sarka, Marinov, Iuri, Prochazka, Tomas, Lysak, Daniel, Jonasova, Anna, Čermák, Jaroslav, Belickova, Monika

“…Idiopathic aplastic anemia (AA) and hypoplastic myelodysplastic neoplasms (MDS-h) are severe hematopoietic disorders characterized by pancytopenia and…”
Get full text

ICCS/ESCCA Consensus Guidelines to detect GPI‐deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders Part 3 – Data Analysis, Reporting and Case Studies by Illingworth, Andrea, Marinov, Iuri, Sutherland, D. Robert, Wagner-Ballon, Orianne, DelVecchio, Luigi

“…Over the past several years, a diverse group of physicians and other laboratory scientists have developed various recommendations and guidelines regarding best…”
Get full text

ICCS/ESCCA Consensus Guidelines to detect GPI‐deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders Part 2 – Reagent Selection and Assay Optimization for High‐Sensitivity Testing by Sutherland, D. Robert, Illingworth, Andrea, Marinov, Iuri, Ortiz, Fernando, Andreasen, John, Payne, Dan, Wallace, Paul K., Keeney, Michael

“…Since publication in 2010 of the International Clinical Cytometry Society (ICCS) Consensus Guidelines for detection of Paroxysmal nocturnal hemoglobinuria…”
Get full text

PHARMACODYNAMICS OF PRASUGREL AND TICAGRELOR IN PATIENTS WITH ACUTE CORONARY SYNDROME AND THE EFFECT OF SWITCHING TO CLOPIDOGREL FOR ECONOMIC AND OTHER REASONS: PLATELET REACTIVITY SUB-STUDY OF THE MULTICENTER RANDOMIZED PRAGUE-18 TRIAL by Miklik, Roman, Knot, Jiri, Kralik, Robin, Kamenik, Martin, Jarkovsky, Jiri, Marinov, Iuri, Motovska, Zuzana

Get full text

Immunophenotyping of Paroxysmal Nocturnal Hemoglobinuria (PNH) by Illingworth, Andrea J, Marinov, Iuri, Sutherland, D Robert

“…Paroxysmal nocturnal hemoglobinuria (PNH) is a rare but often debilitating disease which may lead to death in up to 35% of patients within 5 years if…”
Get more information

High‐sensitivity 5‐, 6‐, and 7‐color PNH WBC assays for both Canto II and Navios platforms by Sutherland, D. Robert, Ortiz, Fernando, Quest, Graeme, Illingworth, Andrea, Benko, Miroslav, Nayyar, Rakesh, Marinov, Iuri

“…Background Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired hematopoietic stem cell disorder characterized by an inability to make…”
Get full text

Sensitive and accurate identification of PNH clones based on ICCS/ESCCA PNH Consensus Guidelines—A summary by Illingworth, Andrea J., Marinov, Iuri, Sutherland, D. Robert

“…Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematopoietic stem cell disorder resulting from the somatic mutation of the X‐linked phosphatidyl‐inositol…”
Get full text

WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML – A Single-center 14-year Experience by Valkova, Veronika, Vydra, Jan, Markova, Marketa, Cerovska, Ela, Vrana, Milena, Marinov, Iuri, Cechova, Hana, Cetkovsky, Petr, Vitek, Antonin, Salek, Cyril

“…This work summarizes our experience with WT1 monitoring before and after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The expression of WT1…”
Get full text

Validation of a single tube 3‐colour immature red blood cell screening assay for the detection and enumeration of small, medium and large paroxysmal nocturnal haemoglobinuria clones by flow cytometry by Marinov, Iuri, Richards, Stephen J., Pešek, Adam, Illingworth, Andrea J., Sutherland, D. Robert

“…Introduction The reliable diagnosis of paroxysmal nocturnal haemoglobinuria (PNH) by flow cytometry is based on mandatory analysis of the erythroid,…”
Get full text

Re Gatti et al (Eur J Haematol 2017 Mar 23. Doi: 10.1111/ejh.12885) by Sutherland, D. Robert, Illingworth, Andrea J., Whitby, Liam, Marinov, Iuri

Get full text

Performance Characteristics of a Non‐Fluorescent Aerolysin‐Based Paroxysmal Nocturnal Hemoglobinuria (PNH) Assay for Simultaneous Evaluation of PNH Neutrophils and PNH Monocytes by Flow Cytometry, Following Published PNH Guidelines by Marinov, Iuri, Illingworth, Andrea J., Benko, Miroslav, Sutherland, D. Robert

“…Background CD157 has been recently reported as a useful glycosylphosphatidylinositol (GPI)‐linked marker for the detection of paroxysmal nocturnal…”
Get full text

CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with paroxysmal nocturnal hemoglobinuria by Sutherland, D. Robert, Richards, Stephen J., Ortiz, Fernando, Nayyar, Rakesh, Benko, Miroslav, Marinov, Iuri, Illingworth, Andrea

“…Background The diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) relies on flow cytometric demonstration of loss of glycosyl‐phosphatidyl inositol…”
Get full text

Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia by Šálek, Cyril, Folber, František, Froňková, Eva, Procházka, Bohumír, Marinov, Iuri, Cetkovský, Petr, Mayer, Jiří, Doubek, Michael

“…Objective To evaluate the prognostic power of minimal residual disease (MRD) monitored by polymerase chain reaction at defined time points during early…”
Get full text

Interferon-[alpha] Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients by Polivkova, Vaclava, Rohon, Peter, Klamova, Hana, Cerna, Olga, Divoka, Martina, Curik, Nikola, Zach, Jan, Novak, Martin, Marinov, Iuri, Soverini, Simona, Faber, Edgar, Machova Polakova, Katerina

“…Bone marrow transplantation or ponatinib treatment are currently recommended strategies for management of patients with chronic myeloid leukemia (CML)…”
Get full text

Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP by Provaznikova, Dana, Rittich, Simon, Malina, Michal, Seeman, Tomas, Marinov, Iuri, Riedl, Magdalena, Hrachovinova, Ingrid

“…Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure…”
Get full text